

16. (Once Amended) A kit for predicting the onset of pre-eclampsia in a pregnant woman, comprising means for assaying a sample from the [women] woman for the levels of free β -human chorionic gonadotrophin (free β -hCG), [and] Inhibin A and unconjugated oestriol (uE₃) present in the sample.

B12
cont

Remarks

By the foregoing amendments, Applicants have amended the international application to place the specification and claims into proper format for U.S. practice. The amendments to claims 1, 3, 5, 8, 9, 11, 13, 15 and 16 have been made to amend claim dependencies and to amend obvious typographical errors. Support for amended claims 1, 5, 11 and 16 can be found in the specification, *inter alia*, at page 3, lines 23-26; and in original claims 2, 12 and 17. Hence, no new matter has been added by the foregoing amendments, and entry and consideration of the same are respectfully requested.

Conclusion

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

09719055:060604
T09090:5506T260

It is respectfully believed that this application is now in condition for examination.

Early notice to this effect is earnestly solicited.

If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

Date: December 7, 2000
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005
(202) 371-2600